| Literature DB >> 24693286 |
Qingqing Zhang1, Zhixiao Wang1, Min Sun1, Mengdie Cao1, Zhenxin Zhu1, Qi Fu1, Yuan Gao2, Jia Mao1, Yanyun Li1, Yun Shi1, Fan Yang1, Shuai Zheng1, Wei Tang2, Yu Duan1, Xiaoping Huang1, Wei He1, Tao Yang1.
Abstract
Background. A recent study has reported that high circulating 25-hydroxyvitamin D [25(OH)D] is associated with low circulating thyroid-stimulating hormone (TSH) levels, but only in younger individuals. The goal of the present study was to explore the relationship between vitamin D status and circulating TSH levels with thyroid autoimmunity and thyroid hormone levels taken into consideration in a population-based health survey of middle-aged and elderly individuals. Methods. A total of 1,424 Chinese adults, aged 41-78 years, were enrolled in this cross-sectional study. Serum levels of 25(OH)D, TSH, thyroid hormones, and thyroid autoantibodies were measured. Results. The prevalence of vitamin D insufficiency was 94.29% in males and 97.22% in females, and the prevalence of vitamin D deficiency was 55.61% in males and 69.64% in females. Vitamin D status was not associated with positive thyroid autoantibodies after controlling for age, gender, body mass index, and smoking status. Higher 25(OH)D levels were associated with lower TSH levels after controlling for age, FT4 and FT3 levels, thyroid volume, the presence of thyroid nodule(s), and smoking status in males. Conclusion. High vitamin D status in middle-aged and elderly males was associated with low circulating TSH levels independent of thyroid hormone levels.Entities:
Year: 2014 PMID: 24693286 PMCID: PMC3947886 DOI: 10.1155/2014/631819
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Clinical and laboratory characteristics of the participants.
| Characteristics | Male ( | Female ( | Total ( |
|---|---|---|---|
| Age (years) | 59.22 ± 9.03 | 59.04 ± 8.20 | 59.11 ± 8.53 |
| BMI (kg/m2) | 24.93 ± 3.38 | 24.66 ± 3.36 | 24.76 ± 3.37 |
| Serum 25 (OH)D (nmol/L) | 47.50 (38.00–59.00) | 42.90 (35.15–53.11)* | 44.68 (36.20–55.30) |
| Serum FT3 (pmol/L) | 4.34 (3.99–4.69) | 4.31 (3.98–4.72) | 4.32 (3.98–4.69) |
| Serum FT4 (pmol/L) | 15.87 (13.10–18.03) | 15.81 (13.22–17.95) | 15.83 (13.18–17.97) |
| Serum TSH ( | 2.06 (1.36–3.30) | 3.03 (1.89–4.60)* | 2.65 (1.62–4.10) |
| Serum TPOAb (IU/mL) | 3.09 (1.07–11.08) | 4.18 (1.24–16.28) | 3.66 (1.15–14.34) |
| Serum TgAb (IU/mL) | 10.08 (6.87–19.22) | 13.19 (7.90–35.66)* | 12.06 (7.31–27.00) |
| Thyroid volume (mL) | 8.44 (6.82–10.06) | 7.24 (5.83–8.82) | 7.74 (6.16–9.40) |
| Presence of thyroid nodule(s) ( | 174 (31.02%) | 339 (39.28%)* | 513 (36.03%) |
| Current smokers ( | 252 (44.92%) | 16 (1.85%)* | 268 (18.82%) |
*Significantly different from males, P < 0.01.
Comparison of clinical and laboratory characteristics based on vitamin D insufficiency.
| Vitamin D insufficiency (1368) | Nonvitamin D insufficiency (56) |
| |
|---|---|---|---|
| Age (years) | 59.07 ± 8.55 | 60.07 ± 8.11 | 0.371 |
| Male sex ( | 529 (38.67%) | 32 (57.14%) | 0.006 |
| BMI (kg/m2) | 24.79 ± 3.40 | 24.21 ± 2.50 | 0.106 |
| Serum FT3 (pmol/L) | 4.39 (3.97–4.69) | 4.48 (4.18–4.75) | 0.094 |
| Serum FT4 (pmol/L) | 15.51 (13.14–17.93) | 16.29 (14.01–18.79) | 0.092 |
| Serum TSH ( | 3.42 (1.62–4.18) | 2.47 (1.54–3.24) | 0.000 |
| Serum TgAb (IU/mL) | 84.26 (7.26–27.77) | 21.12 (8.38–22.40) | 0.000 |
| Serum TPOAb (IU/mL) | 40.45 (1.17–14.33) | 16.77 (0.99–14.99) | 0.000 |
| Thyroid volume (mL) | 8.43 (6.12–9.35) | 8.71 (6.53–10.62) | 0.476 |
| Presence of thyroid nodule(s) ( | 495 (36.18%) | 18 (32.14%) | 0.537 |
| Current smokers ( | 814 (59.50%) | 37 (66.07%) | 0.326 |
Determinants of positive serum thyroid antibodies.
| Serum TgAb | Serum TPOAb | Serum TgAb and/or TPOAb | ||||
|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) |
| Adjusted OR (95% CI) |
| Adjusted OR (95% CI) |
| |
| Age (years) | 0.997 (0.974–1.022) | 0.838 | 1.007 (0.983–1.032) | 0.558 | 1.009 (0.987–1.030) | 0.431 |
| Male sex | 2.738 (1.526–4.910) | 0.001 | 2.200 (1.267–3.821) | 0.005 | 2.524 (1.550–4.110) | 0.000 |
| BMI (kg/m2) | 1.035 (0.974–1.099) | 0.266 | 1.040 (0.979–1.106) | 0.204 | 1.039 (0.984–1.097) | 0.166 |
| Smoking status | 0.786 (0.368–1.676) | 0.532 | 1.308 (0.685–2.499) | 0.415 | 1.052 (0.578–1.916) | 0.868 |
| Serum 25(OH)D (nmol/L) | 0.992 (0.979–1.004) | 0.188 | 0.999 (0.987–1.010) | 0.818 | 0.997 (0.986–1.009) | 0.660 |
Standardized regression coefficients of variables in relation to serum TSH according to gender.
| Male (561) | Female (863) | |||
|---|---|---|---|---|
| Beta |
| Beta |
| |
| Age (years) | −0.012 | 0.836 | −0.023 | 0.647 |
| Serum FT3 (pmol/L) | 0.069 | 0.244 | −0.043 | 0.399 |
| Serum FT4 (pmol/L) | −0.040 | 0.501 | −0.066 | 0.201 |
| Presence of TgAb (%) | 0.029 | 0.636 | 0.098 | 0.060 |
| Presence of TPOAb (%) | −0.002 | 0.971 | 0.056 | 0.284 |
| Thyroid volume (mL) | −0.152 | 0.009 | −0.056 | 0.262 |
| Presence of thyroid nodule(s) (%) | −0.025 | 0.669 | −0.116 | 0.023 |
| Current smokers ( | −0.054 | 0.361 | −0.001 | 0.985 |
| Serum 25(OH)D (nmol/L) | −0.166 | 0.004 | −0.001 | 0.983 |
Standardized regression coefficients of variables in relation to serum TSH in males with negative serum antibodies.
| Serum TgAb | Serum TPOAb | Serum TgAb and/or TPOAb | ||||
|---|---|---|---|---|---|---|
| Beta |
| Beta |
| Beta |
| |
| Age (years) | 0.024 | 0.686 | 0.019 | 0.749 | 0.006 | 0.921 |
| Serum FT3 (pmol/L) | 0.030 | 0.593 | 0.092 | 0.122 | 0.074 | 0.228 |
| Serum FT4 (pmol/L) | 0.020 | 0.726 | −0.037 | 0.535 | −0.028 | 0.648 |
| Thyroid volume (mL) | −0.165 | 0.003 | −0.170 | 0.004 | −0.154 | 0.011 |
| Presence of thyroid nodule(s) (%) | −0.035 | 0.532 | −0.020 | 0.736 | −0.024 | 0.696 |
| Current smokers ( | −0.064 | 0.264 | −0.060 | 0.313 | −0.067 | 0.277 |
| Serum 25(OH)D (nmol/L) | −0.157 | 0.004 | −0.166 | 0.004 | −0.184 | 0.002 |